The cardiac nuclear stress test agents Lexiscan, or regadenoson, and Adenoscan, or adenosine, are FDA approved for use during cardiac stress tests in patients who cannot exercise adequately.

The side effect is rare but serious, and related to two specific injectable drugs: Lexiscan and Adenoscan, which are both manufactured by Astellas Pharma US. A typical cardiac nuclear stress test ...

a person may be allergic to the tracer used during the test. Two drugs used for nuclear stress tests — regadenoson (Lexiscan) and adenosine (Adenoscan) — carry a rare risk of heart attack and ...

Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI ...

The U.S. Food and Drug Administration warned physicians on Wednesday that two chemicals used to conduct cardiovascular stress ... heart attacks and 29 deaths following administration with Lexiscan ...

The U.S. Food and Drug Administration has issued a warning that there is a rare but serious risk of heart attack or death associated with the use of cardiac nuclear stress test agents Lexiscan ...

The FDA has issued a safety announcement warning health care professionals of rare but serious risk for MI and death with the use of the cardiac nuclear stress test agents regadenoson and adenosine.

Pharmacological stress testing can be done using either regadenoson (Lexiscan ... are inhibiting the heart rate increase needed, the sensitivity of the stress test to detect coronary stenosis ...

Fourteen years after it launched Lexiscan in the U.S., Astellas is ... who don’t have the physical ability to undergo a cardiac stress test. While the court granted Astellas an interim ...

Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac ... other nuclear stress test agents ...